Navigation Links
Bionovo to Present at Merriman Curhan Ford's Investor Summit 2008 on September 15th
Date:9/12/2008

EMERYVILLE, Calif., Sept. 12 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective drugs in the areas of women's health and cancer, announced today that Dr. Isaac Cohen, Chairman and CEO, and Dr. Mary Tagliaferri, President and Chief Medical Officer of Bionovo, will be presenting at the Merriman Curhan Ford's 5th annual Investor Summit on September 15, 2008 at 2:15 p.m. This event will be held at the Mark Hopkins InterContinental Hotel in San Francisco.

The presentation will be webcast and can be viewed via Bionovo's website at http://webcasts.bionovo.com. A webcast replay will become available shortly after the presentation ends and will continue to be accessible for 90 days via Bionovo's website.

More information about the conference can be found at: http://mcfco.com/AboutUs/Conferences_YearBook.php?ConferenceName=InvestorSu mmi t2008

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol BNVI. For more information about Bionovo and its programs, visit http://www.bionovo.com.

About Merriman Curhan Ford

Merriman Curhan Ford Group, Inc. is a financial services firm focused on fast-growing companies and the institutions who invest in them. The company offers high-quality investment banking, equity research, institutional services, primary market research, asset management and corporate & venture services, and specializes in four growth industry sectors: CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. For more information, please go to http://www.mcfco.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo to Present at Canaccord Adams Global Growth Conference
2. Bionovo Reports Second Quarter 2008 Financial Results
3. Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
4. Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds
5. Bionovo Reports First Quarter 2008 Financial Results
6. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
7. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
8. Louis Drapeau Joins Bionovos Board of Directors
9. George Butler Joins Bionovos Board of Directors
10. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
11. Bionovo Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... Michael Fitzmaurice recently became double board-certified in surgery and surgery of the hand ... Dr. Fitzmaurice is no stranger to going above and beyond in his pursuit ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Scientists at ... line options being tried for mesothelioma may be hampering the research that could lead ... research. Click here to read it now. , The team evaluated 98 ...
(Date:5/25/2016)... ... 25, 2016 , ... Lady had been battling arthritis since the age of ... left knee. Lady’s owner Hannah sought the help of Dr Jeff Christiansen of ... her cruciate ligament and help with the pain of Lady’s arthritis. Dr Christiansen suggested ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies for a range ... by research at Worcester Polytechnic Institute (WPI) that yielded a newly patented method ... , The novel method, developed by WPI faculty members Raymond Page, PhD, professor ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
Breaking Biology News(10 mins):